NAGE Niagen Bioscience, Inc.
8-K Current Report
Filed: March 4, 2026
Health Care
Medicinal Chemicals & Botanical ProductsNiagen Bioscience, Inc. (NAGE) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 4, 2026
- • Actual figures in Exhibit 99.1 press release — key metrics not disclosed in this filing item
Item 7.01 · Regulation FD Disclosure
- • Corporate presentation published March 4, 2026, now available on company website and filed as Exhibit 99.2
- • Reg FD disclosure ensures all investors receive simultaneous access to material company information in the presentation
Other Niagen Bioscience, Inc. 8-K Filings
Get deeper insights on Niagen Bioscience, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.